Poly Adenosine Diphosphate Ribose Polymerase Market, by Drug (Olaparib, Rucaparib, Niraparib, and Others), by Cancer Type (Prostate Cancer, Ovarian Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

  • To Be Published : Dec 2018 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Poly adenosine diphosphate ribose polymerase (PARP) is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins. These proteins aid in restoring the damage in DNA caused due to various factors such as exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment. PARP inhibitors aid in blocking the enzyme important for the repair of single stranded breaks in DNA that effectively destroys cancer cells.

These inhibitors play an effective role in current cancer-combating strategies, owing to its effectiveness in eliminating cancer cells as compared to the existing ovarian cancer treatments. Drugs such as Talazoparib and Veliparib that aid in treatment of ovarian cancer are in phase III clinical trials. Such research and development activities is a key factor contributing to the global poly adenosine diphosphate ribose polymerase market growth.

Poly Adenosine Diphosphate Ribose Polymerase Market Drivers

High prevalence of various types of cancer is a key factor contributing to growth of the global poly adenosine diphosphate ribose polymerase market. Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its invasive nature and prolonged duration of disease. According to American Cancer Society (ASC), around 22,240 women are expected to be diagnosed with ovarian cancer, and around 14,070 deaths are expected from the disease in 2018.

Furthermore, introduction of new drugs has propelled the poly adenosine diphosphate ribose polymerase market growth. For instance, the U.S. Food & Drug Administration approved 3 PARP inhibitors—Olaparib, Rucaparib, and Niraparib. These drugs are a potential alternative that aid in treatment of ovarian and other cancers after paclitaxel.

Moreover, combination of these PARP inhibitors with other therapies such as monoclonal antibodies is under research. For instance, in May 2018, TESARO, Inc.—an oncology-focused biopharmaceutical company— announced collaboration with Genentech—a member of the Roche Group—to evaluate the combination of the PD-L1 antibody— Atezolizumab (TECENTRIQ), the MEK inhibitor cobimetinib (COTELLIC), and TESARO’s PARP inhibitor ZEJULA (Niraparib) — in patients with platinum-sensitive ovarian cancer. In April 6, 2018, the U.S. Food and Drug Administration (FDA) approved Rubraca (rucaparib) tablets --manufactured by Clovis Oncology Inc.—for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients.

Moreover, robust pipeline of poly adenosine diphosphate ribose polymerase inhibitors is major factor contributing to the market growth over the forecast period. For instance, AbbVie’s and Pfizer Inc. have Veliparib and Talazoparib – in phase 3 clinical trials. Furthermore, these drugs are expected to be effective in the treatment of diseases other than ovarian cancer and the research for expanding indications is underway as well. For instance, Talazoparib developed by Pfizer Inc., is in phase 3 clinical trials for treatment of prostate cancer.

However, various side effects such as possibility of myelodysplastic syndrome or acute myeloid leukemia due to Lynparza (Olaparib), resistance to PARP inhibitors, and regulatory challenges are some of the factors that are expected to hamper the poly adenosine diphosphate ribose polymerase market growth.

Poly Adenosine Diphosphate Ribose Polymerase Market Regional Insights

North America and Europe are expected to witness significant growth in the poly adenosine diphosphate ribose polymerase market over the forecast period. Increasing demand for approved drugs, owing to high prevalence of various types of cancer is expected to facilitate growth of the market, in the U.S. For instance, according to American Cancer Society (ASC), around 164,690 new cases are expected to be diagnosed with prostate cancer in 2018.

New product launches and robust pipeline of PARP inhibitors is expected to boost the North America, and Europe PARP inhibitors market growth over the forecast period. For instance, Clovis Oncology launched Rubraca (Rucaparib) in 2016, and Tesaro, Inc. launched Zejula (Niraparib) in 2017. Moreover, Lynparza (Olaparib) manufactured by AstraZeneca Plc was approved by the U.S. Food & Drug Administration for the treatment of germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer in January 2018.

Poly Adenosine Diphosphate Ribose Polymerase Market Key Player

Key players operating in the poly adenosine diphosphate ribose polymerase market include Tesaro Inc., Clovis Oncology, AstraZeneca, Pfizer, Inc., and AbbVie Inc.

Poly Adenosine Diphosphate Ribose Polymerase Market Taxonomy

The global poly adenosine diphosphate ribose polymerase market is segmented on the basis of drug, cancer type, distribution channel, and region.

By Drug -

  • Olaparib
  • Rucaparib
  • Niraparib
  • Others

By Cancer Type -

  • Prostate Cancer
  • Ovarian Cancer
  • Others

By Distribution Channel -

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region -

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.
Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.